Alexandra Petiet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Petiet has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Marc Dhenain
Neuro-Bicêtre, Inserm U1195, CNRS EMR2000, Université Paris-Saclay, Bâtiment Gregory Pincus, Le Kremlin Bicêtre, France
3 shared publications - Anne Bertrand
MRC Oulu, Oulu University Hospital, Oulu, Finland
1 shared publication - Benoît Delatour
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France
1 shared publication Christopher J. Wiggins
1 shared publication- Diane Houitte
Institute of Biomedical Imaging, Molecular Imaging Research Center CNRS CEA URA 2210, Fontenay-aux-Roses, France
1 shared publication - Fanny Petit
CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, Fontenay-aux-Roses, France
1 shared publication
Latest Publications
- 1 August 2012
- Published by Elsevier in Neurobiology of Aging
- Vol. 33 (8) , 1533-1544
Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice
- 1 August 2012
- Published by Elsevier in Neurobiology of Aging
- Vol. 33 (8) , 1533-1544
Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice
- Open Access
- 1 August 2011
- Published by Springer Nature
- Vol. 771, 293-308
Models of Neurodegenerative Disease – Alzheimer’s Anatomical and Amyloid Plaque Imaging
Alzheimer’s disease (AD) is an important social and economic issue for our societies. The development of therapeutics against this severe dementia requires assessing the effects of new drugs in animal models thanks to dedicated biomarkers. According to the amyloid cascade hypothesis, β-amyloid deposits are at the origin of most of the lesions associated with AD. These extracellular deposits are therefore one of the main targets in therapeutical strategies. Aβ peptides can be revealed histologically with specific dyes or antibodies, or by magnetic resonance microscopy (μMRI) that uses their association with iron as a source of signal. The microscopic size of the lesions necessitates the development of specific imaging protocols. Most protocols use T 2-weighted sequences that reveal the aggregates as hypointense spots. This chapter describes histological methods that reveal amyloid plaques with specific stains and MR-imaging protocols for in vivo and ex vivo MR imaging of AD mice.
- 1 August 2011
- Published by Springer Nature
- Vol. 771, 293-308
Open AccessModels of Neurodegenerative Disease – Alzheimer’s Anatomical and Amyloid Plaque Imaging
Alzheimer’s disease (AD) is an important social and economic issue for our societies. The development of therapeutics against this severe dementia requires assessing the effects of new drugs in animal models thanks to dedicated biomarkers. According to the amyloid cascade hypothesis, β-amyloid deposits are at the origin of most of the lesions associated with AD. These extracellular deposits are therefore one of the main targets in therapeutical strategies. Aβ peptides can be revealed histologically with specific dyes or antibodies, or by magnetic resonance microscopy (μMRI) that uses their association with iron as a source of signal. The microscopic size of the lesions necessitates the development of specific imaging protocols. Most protocols use T 2-weighted sequences that reveal the aggregates as hypointense spots. This chapter describes histological methods that reveal amyloid plaques with specific stains and MR-imaging protocols for in vivo and ex vivo MR imaging of AD mice.
- 1 February 2011
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 7 (1) , 8-15
Improvement of Microscopic MR Imaging of Amyloid Plaques with Targeting and Non-Targeting Contrast Agents
Abstract: Overaccumulation of β-amyloid in the brain is believed to be a primary event in the development of Alzheimers disease (AD). This amyloid is the target of drugs currently under development for the treatment of AD, which makes imaging amyloid plaques essential. Magnetic resonance imaging (MRI) has the resolution required to resolve these microscopic lesions (∼ 50 μm). In the absence of any contrast agent, the source of MR contrast in the amyloid plaques comes from the accumulation of iron, which shows as hypointense spots in T2, T2* or susceptibility-weighted images. Iron deposition in the brain is an age-related phenomenon and its accumulation occurs mainly in iron-rich regions. For plaques weakly loaded with iron, whose detection is much more challenging, the use of exogenous contrast agents (CA) becomes necessary. This article describes (1) targeted CAs made of a paramagnetic element like Gadolinium linked to a pharmacophore that targets amyloid, and (2) non-targeted CAs, an alternative to enhance amyloid plaque visualization. A background on CAs is also presented, and current issues related to contrast-enhanced MR imaging, including difficulties in delivering these agents across the blood-brain barrier, are also discussed.
- 1 February 2011
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 7 (1) , 8-15
Improvement of Microscopic MR Imaging of Amyloid Plaques with Targeting and Non-Targeting Contrast Agents
Abstract: Overaccumulation of β-amyloid in the brain is believed to be a primary event in the development of Alzheimers disease (AD). This amyloid is the target of drugs currently under development for the treatment of AD, which makes imaging amyloid plaques essential. Magnetic resonance imaging (MRI) has the resolution required to resolve these microscopic lesions (∼ 50 μm). In the absence of any contrast agent, the source of MR contrast in the amyloid plaques comes from the accumulation of iron, which shows as hypointense spots in T2, T2* or susceptibility-weighted images. Iron deposition in the brain is an age-related phenomenon and its accumulation occurs mainly in iron-rich regions. For plaques weakly loaded with iron, whose detection is much more challenging, the use of exogenous contrast agents (CA) becomes necessary. This article describes (1) targeted CAs made of a paramagnetic element like Gadolinium linked to a pharmacophore that targets amyloid, and (2) non-targeted CAs, an alternative to enhance amyloid plaque visualization. A background on CAs is also presented, and current issues related to contrast-enhanced MR imaging, including difficulties in delivering these agents across the blood-brain barrier, are also discussed.